Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A PHASE-II TRIAL OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN THE TREATMENT OF METASTATIC CARCINOMA OF THE UTERINE CERVIX
Autore:
PAPADIMITRIOU CA; DIMOPOULOS MA; GIANNAKOULIS N; SARRIS K; VASSILAKOPOULOS G; AKRIVOS T; VOULGARIS Z; VLAHOS G; DIAKOMANOLIS E; MICHALAS S;
Indirizzi:
ZARGORAS 2 AMAROUSSION 15125 ATHENS GREECE UNIV ATHENS,SCH MED,ALEXANDRA HOSP,DEPT CLIN THERAPEUT GR-11527 ATHENS GREECE ALEXANDRA HOSP,DEPT RADIAT ONCOL ATHENS GREECE
Titolo Testata:
Cancer
fascicolo: 12, volume: 79, anno: 1997,
pagine: 2391 - 2395
SICI:
0008-543X(1997)79:12<2391:APTOMV>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
SQUAMOUS-CELL CARCINOMA; CANCER; CHEMOTHERAPY; IFOSFAMIDE; BLEOMYCIN;
Keywords:
CERVICAL CARCINOMA; METASTATIC; RECURRENT; CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
15
Recensione:
Indirizzi per estratti:
Citazione:
C.A. Papadimitriou et al., "A PHASE-II TRIAL OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN IN THE TREATMENT OF METASTATIC CARCINOMA OF THE UTERINE CERVIX", Cancer, 79(12), 1997, pp. 2391-2395

Abstract

BACKGROUND. Patients with metastatic carcinoma of the uterine cervix have limited survival. Thus, new chemotherapeutic agents and combinations are needed to improve patient outcome. METHODS. Twenty-seven patients with Stage IV primary or recurrent carcinoma of the uterine cenix were assigned to chemotherapy treatment at 4-week intervals with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The treatmentwas comprised of methotrexate, 30 mg/m(2) administered intravenously (i.v.) on Days 1, 15, and 22; vinblastine, 3 mg/m(2) i.v. on Days 2, 15, and 22; doxorubicin, 30 mg/m(2) i.v. on Day 2; and cisplatin, 70 mg/m(2) i.v. on Day 2. Granulocyte-colony stimulating factor (G-CSF) wasgiven subcutaneously on Days 6-10 at a dose of 5 mu g/kg. RESULTS. After a median of 4 cycles (a maximum of 6 in responders), the authors observed objective responses in 14 patients (52%), including 3 completeresponses (11%) and 11 partial responses (41%). Median overall survival was 11 months (range, 4-15+ months), and median progression free survival of the responders was 8 months (range, 6-15+ months). Toxicity was acceptable and included neutropenia, alopecia, vomiting, and stomatitis. CONCLUSIONS. MVAC is an active regimen in the treatment of patients with advanced or recurrent carcinoma of the uterine cervix. It produced responses in one-half of the patients in this study, and it canbe administered on an outpatient basis. The addition of G-CSF appearsto reduce hematologic toxicity. (C) 1997 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 08:43:34